Biotechnology firm Crucell will be delisted from the Amsterdam and Swiss stock exchanges on April 12 following its takeover by US pharmaceuticals company Johnson & Johnson.
Johnson & Johnson bought the Leiden-based firm for some €1.75bn in February and now controls almost 99% of the shares outstanding. The US firm will now embark on a buy-out procedure to mop up the remaining shares.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation